Linvoseltamab Clinical Trials (2026): 20 Studies for Multiple Myeloma & Smoldering Multiple Myeloma (SMM)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
20 Linvoseltamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 13 indications (including Multiple Myeloma & Smoldering Multiple Myeloma (SMM)) and 6,290 total planned enrollment. 4 Phase 3 Linvoseltamab trials and 5 Phase 2, 2 Phase 4 are listed. 19 Linvoseltamab clinical trials are actively recruiting at 58 U.S. sites across 19 states. Most recent activity: NCT07428369 (May 2038).
Where to Participate: All Linvoseltamab Trial Sites in the U.S. (58 sites across 19 states)
Every actively recruiting Linvoseltamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope | Duarte91010 | NCT06292780 | Map |
| CA | Scripps Clinic Torrey Pines | La Jolla92037 | NCT05137054 | Map |
| CA | University of California Los Angeles (UCLA) | Los Angeles90095 | NCT05828511 | Map |
| CA | UC Irvine Health | Orange92868 | NCT05828511 | Map |
| CO | Colorado Blood Cancer Institute/SCRI | Denver80218 | NCT05828511 | Map |
| CO | Colorado Blood Cancer Institute/SCRI | Denver80218 | NCT06292780 | Map |
| FL | University of Miami | Miami33136 | NCT06376526 | Map |
| FL | University of Miami | Miami33136 | NCT06910124 | Map |
| FL | Moffitt Cancer Center - McKinley Drive | Tampa33612 | NCT03761108 | Map |
| FL | University of South Florida | Tampa33613 | NCT06369467 | Map |
| GA | Emory University - Winship Cancer Institute | Atlanta30322 | NCT06369467 | Map |
| GA | Emory University Hospital | Atlanta30322 | NCT03761108 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30004 | NCT05137054 | Map |
| IN | Indiana University Health Simon Cancer Center | Indianapolis46202 | NCT05137054 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT05828511 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT03761108 | Map |
| MD | Johns Hopkins Hospital | Baltimore21287 | NCT06140524 | Map |
| MA | Dana Farber / Harvard Cancer Center | Boston02215 | NCT07393282 | Map |
| MA | Dana Farber/Harvard Cancer Center | Boston02215 | NCT05137054 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06140524 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06369467 | Map |
| MI | University of Michigan Health | Ann Arbor48109 | NCT06140524 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT05828511 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT05137054 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT06292780 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT05137054 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT05828511 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14263 | NCT06292780 | Map |
| NY | Perlmutter Cancer Center at NYU Langone Hospital - Long Island | Mineola11501 | NCT05828511 | Map |
| NY | Columbia University _ New York Presbyterian | New York10032 | NCT05828511 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT03761108 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT06369467 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10021 | NCT07222761 | Map |
| NY | New York Presbyterian Hospital Columbia University Medical Center | New York10032 | NCT05137054 | Map |
| NY | NYU Langone Health Perlmutter Cancer Center | New York10016 | NCT06140524 | Map |
| NY | Perlmutter Cancer Center | New York10016 | NCT05828511 | Map |
| NY | Weill Cornell Medicine/New York Presbyterian Hospital | New York10021 | NCT05137054 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT05828511 | Map |
| NY | Stony Brook University Hospital | Stony Brook11794 | NCT06140524 | Map |
| NC | University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT05137054 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT05828511 | Map |
| NC | Duke University Health System (DUHS) | Durham27705 | NCT05828511 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05137054 | Map |
| OH | Ohio State University | Columbus43210 | NCT06292780 | Map |
| OH | Ohio State University James Cancer Hospital | Columbus43210 | NCT03761108 | Map |
| OH | OhioHealth | Columbus43214 | NCT07222761 | Map |
| OH | The Ohio State University James Cancer Hospital | Columbus43210 | NCT05137054 | Map |
| OR | Oregon Health and Science University (OHSU) Marquam Hill Campus | Portland97239 | NCT03761108 | Map |
| PA | The Children's Hospital of Philadelphia | Philadelphia19104 | NCT06369467 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT06140524 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06292780 | Map |
| TX | University of Texas Southwestern | Dallas75390 | NCT05137054 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06292780 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT05828511 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT07181941 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT03761108 | Map |
| WA | University of Washington | Seattle98109 | NCT06140524 | Map |
| WA | VA Puget Sound Health Care System | Seattle98108 | NCT05137054 | Map |
Linvoseltamab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | not yet recruiting | Total |
|---|---|---|---|---|
| P1 | 2 | 2 | ||
| P1/P2 | 6 | 6 | ||
| P2 | 3 | 1 | 1 | 5 |
| P2/P3 | 1 | 1 | ||
| P3 | 4 | 4 | ||
| P4 | 2 | 2 |
Recruiting Linvoseltamab clinical trials (19)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07428369 | LINKER-MM8A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) | P2/P3 | Multiple Myeloma (MM) | 1,570 | Jun 2026 |
| NCT07474961 | BLOOD-doseBLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. | P4 | Waldenstrom Macroglobulinaemia | 400 | Mar 2027 |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | P3 | Multiple Myeloma | 1,000 | Dec 2025 |
| NCT05828511 | LINKER-MM4A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | P1/P2 | Multiple Myeloma | 149 | Dec 2023 |
| NCT06669247 | COSTIMMA Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma | P1/P2 | Relapsed/Refractory Multiple Myeloma | 186 | Dec 2024 |
| NCT06292780 | LINKER-AL2A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) | P1/P2 | Relapsed/Refractory Systemic Light Chain Amyloidosis | 220 | Aug 2024 |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | P1 | Multiple Myeloma | 317 | Aug 2022 |
| NCT07222761 | LINKER-MM5A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | P3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | 915 | Jan 2026 |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | P1/P2 | Relapsed Refractory Multiple Myeloma (RRMM) | 150 | Mar 2026 |
| NCT07393282 | LINKER-SMM2A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) | P3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | 270 | May 2026 |
| NCT03761108 | LINKER-MM1Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | P1/P2 | Multiple Myeloma | 387 | Jan 2019 |
| NCT05730036 | LINKER-MM3A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | P3 | Relapsed Refractory Multiple Myeloma (RRMM) | 410 | Sep 2023 |
| NCT06910124 | L2Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse | P2 | Multiple Myeloma | 32 | Dec 2025 |
| NCT06140524 | LINKER-MGUS1A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | P2 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | 116 | Sep 2024 |
| NCT06376526 | IMMUNOPLANTIMMUNOPLANT for Newly Diagnosed Multiple Myeloma | P2 | Multiple Myeloma | 28 | Aug 2024 |
| NCT07009899 | RECLAIMBCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) | P2 | Multiple Myeloma | 34 | Jul 2026 |
| NCT07609940 | POPLINAdult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | P4 | Relapsed/Refractory Multiple Myeloma (RRMM) | 30 | Jul 2026 |
| NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma | P1/P2 | Recurrent Multiple Myeloma | 30 | Mar 2026 |
| NCT06369467 | Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy | P1 | Food Allergy | 6 | May 2024 |
Linvoseltamab clinical trials by indication
Multiple Myeloma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06932562 | — | P3 | recruiting | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant |
| NCT05828511 | LINKER-MM4 | P1/P2 | recruiting | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment |
| NCT05137054 | — | P1 | recruiting | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments |
| NCT03761108 | LINKER-MM1 | P1/P2 | recruiting | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma |
| NCT06910124 | L2 | P2 | recruiting | Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse |
| NCT06376526 | IMMUNOPLANT | P2 | recruiting | IMMUNOPLANT for Newly Diagnosed Multiple Myeloma |
| NCT07009899 | RECLAIM | P2 | not yet recruiting | BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) |
Relapsed Refractory Multiple Myeloma (RRMM) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07455851 | — | P1/P2 | recruiting | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma |
| NCT05730036 | LINKER-MM3 | P3 | recruiting | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma |
Waldenstrom Macroglobulinaemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07474961 | BLOOD-dose | P4 | not yet recruiting | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. |
Relapsed/Refractory Multiple Myeloma (RRMM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07609940 | POPLIN | P4 | not yet recruiting | Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) |
Multiple Myeloma (MM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07428369 | LINKER-MM8 | P2/P3 | not yet recruiting | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) |
High Risk Smoldering Multiple Myeloma (HR-SMM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07393282 | LINKER-SMM2 | P3 | recruiting | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) |
Recurrent Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07181941 | — | P1/P2 | recruiting | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma |
Relapsed and/or Refractory Multiple Myeloma (RRMM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07222761 | LINKER-MM5 | P3 | recruiting | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) |
Relapsed/Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06669247 | COSTIMM | P1/P2 | recruiting | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma |
Monoclonal Gammopathy of Undetermined Significance (MGUS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06140524 | LINKER-MGUS1 | P2 | recruiting | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma |
Relapsed/Refractory Systemic Light Chain Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06292780 | LINKER-AL2 | P1/P2 | recruiting | A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) |
Food Allergy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06369467 | — | P1 | recruiting | Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy |
Smoldering Multiple Myeloma (SMM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05955508 | — | P2 | active not recruiting | A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma |
Linvoseltamab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| BLOOD-dose | NCT07474961 | P4 | not yet recruiting | Waldenstrom Macroglobulinaemia | 400 | PMID 40049207 |
| POPLIN | NCT07609940 | P4 | not yet recruiting | Relapsed/Refractory Multiple Myeloma (RRMM) | 30 | — |
| LINKER-MM5 | NCT07222761 | P3 | recruiting | Relapsed and/or Refractory Multiple Myeloma (RRMM) | 915 | — |
| LINKER-SMM2 | NCT07393282 | P3 | recruiting | High Risk Smoldering Multiple Myeloma (HR-SMM) | 270 | — |
| LINKER-MM3 | NCT05730036 | P3 | recruiting | Relapsed Refractory Multiple Myeloma (RRMM) | 410 | — |
| L2 | NCT06910124 | P2 | recruiting | Multiple Myeloma | 32 | — |
| LINKER-MGUS1 | NCT06140524 | P2 | recruiting | Monoclonal Gammopathy of Undetermined Significance (MGUS) | 116 | — |
| IMMUNOPLANT | NCT06376526 | P2 | recruiting | Multiple Myeloma | 28 | — |
| RECLAIM | NCT07009899 | P2 | not yet recruiting | Multiple Myeloma | 34 | — |
All Linvoseltamab trials (20)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07428369 | LINKER-MM8 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) | P2/P3 | not yet recruiting | 1,570 | Regeneron Pharmaceuticals | Jun 2026 |
| NCT07474961 | BLOOD-dose | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. | P4 | not yet recruiting | 400 | Anne Louise Tølbøll Sørensen | Mar 2027 |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | P3 | recruiting | 1,000 | European Myeloma Network B.V. | Dec 2025 | |
| NCT05828511 | LINKER-MM4 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | P1/P2 | recruiting | 149 | Regeneron Pharmaceuticals | Dec 2023 |
| NCT06669247 | COSTIMM | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma | P1/P2 | recruiting | 186 | Regeneron Pharmaceuticals | Dec 2024 |
| NCT06292780 | LINKER-AL2 | A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) | P1/P2 | recruiting | 220 | Regeneron Pharmaceuticals | Aug 2024 |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | P1 | recruiting | 317 | Regeneron Pharmaceuticals | Aug 2022 | |
| NCT07222761 | LINKER-MM5 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | P3 | recruiting | 915 | Regeneron Pharmaceuticals | Jan 2026 |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | P1/P2 | recruiting | 150 | Regeneron Pharmaceuticals | Mar 2026 | |
| NCT07393282 | LINKER-SMM2 | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) | P3 | recruiting | 270 | Regeneron Pharmaceuticals | May 2026 |
| NCT03761108 | LINKER-MM1 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | P1/P2 | recruiting | 387 | Regeneron Pharmaceuticals | Jan 2019 |
| NCT05730036 | LINKER-MM3 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | P3 | recruiting | 410 | Regeneron Pharmaceuticals | Sep 2023 |
| NCT05955508 | A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | P2 | active not recruiting | 40 | Regeneron Pharmaceuticals | Jan 2024 | |
| NCT06910124 | L2 | Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse | P2 | recruiting | 32 | Dickran Kazandjian, MD | Dec 2025 |
| NCT06140524 | LINKER-MGUS1 | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | P2 | recruiting | 116 | Regeneron Pharmaceuticals | Sep 2024 |
| NCT06376526 | IMMUNOPLANT | IMMUNOPLANT for Newly Diagnosed Multiple Myeloma | P2 | recruiting | 28 | Dickran Kazandjian, MD | Aug 2024 |
| NCT07009899 | RECLAIM | BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) | P2 | not yet recruiting | 34 | Medical College of Wisconsin | Jul 2026 |
| NCT07609940 | POPLIN | Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | P4 | not yet recruiting | 30 | Regeneron Pharmaceuticals | Jul 2026 |
| NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma | P1/P2 | recruiting | 30 | Fred Hutchinson Cancer Center | Mar 2026 | |
| NCT06369467 | Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy | P1 | recruiting | 6 | Regeneron Pharmaceuticals | May 2024 |
Linvoseltamab clinical trials: frequently asked questions
- How many Linvoseltamab clinical trials are there?
- 20 Linvoseltamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 15 are actively recruiting participants.
- Are Linvoseltamab clinical trials recruiting in 2026?
- Yes — 15 Linvoseltamab trials are actively recruiting in 2026, with 58 U.S. sites across 19 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Linvoseltamab being studied for?
- Linvoseltamab is being studied for Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma (MM), Recurrent Multiple Myeloma and 9 more. The trials are grouped by indication on this page.
- What phase is Linvoseltamab in?
- Linvoseltamab clinical trials span 2 Phase 4, 4 Phase 3, 5 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Linvoseltamab clinical trials?
- The lead sponsor across the most Linvoseltamab trials is Regeneron Pharmaceuticals, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Linvoseltamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: